Literature DB >> 18343443

Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival.

Helen Shi Stafford1, Sidney L Saltzstein, Suzuho Shimasaki, Catherine Sanders, Tracy M Downs, Georgia Robins Sadler.   

Abstract

PURPOSE: We used a population based cancer registry to examine trends in renal cell carcinoma incidence and survival among 4 racial/ethnic groups (white, black, Hispanic and Asian/Pacific Islander) and both genders.
MATERIALS AND METHODS: Race/ethnicity, gender, age, staging, length of survival and cause of death data were analyzed using 39,434 cases of renal cell carcinoma from 1988 to 2004 from the California Cancer Registry. Annual age adjusted incidence rates and relative survival rates were calculated for the racial/ethnic and gender groups. These rates and the percent of localized cancer were plotted by year, and Microsoft Excel was used to calculate linear regression equations. Median age was also calculated. Z-tests and chi-square tests were performed to determine p values.
RESULTS: An increase in renal cell carcinoma incidence was found with localized cancer accounting for most of the increase. Black patients had a significantly higher incidence rate (p <0.0001) and lower survival rate (p <0.0001) than all other races/ethnicities despite having more localized cancer (p <0.005). Black patients were also diagnosed at a younger age (p <0.0001) than their counterparts. On the other hand Asian/Pacific Islanders had a lower incidence rate (p <0.0001) and higher survival rate (p <0.05) than all other races/ethnicities. Males had approximately twice the incidence rate of females and a lower survival rate (p <0.005).
CONCLUSIONS: Higher incidence rates and lower survival rates were identified among black and male patients compared to their counterparts, while Asian/Pacific Islanders showed the opposite trends. Such racial/ethnic and gender disparities in renal cell carcinoma incidence and survival may help elucidate biological, behavioral and environmental factors that can potentially be addressed.

Entities:  

Mesh:

Year:  2008        PMID: 18343443      PMCID: PMC2677163          DOI: 10.1016/j.juro.2008.01.027

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Cancer incidence in five continents. Volume VIII.

Authors: 
Journal:  IARC Sci Publ       Date:  2002

2.  The genetic make-up of renal cell tumors.

Authors:  M A Noordzij; G H Mickisch
Journal:  Urol Res       Date:  2004-08

Review 3.  The association between obesity and the progression of prostate and renal cell carcinoma.

Authors:  Christopher L Amling
Journal:  Urol Oncol       Date:  2004 Nov-Dec       Impact factor: 3.498

4.  Excess mortality among blacks and whites in the United States.

Authors:  A T Geronimus; J Bound; T A Waidmann; M M Hillemeier; P B Burns
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

5.  Rising incidence of renal cell cancer in the United States.

Authors:  W H Chow; S S Devesa; J L Warren; J F Fraumeni
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

Review 6.  Increased incidence of serendipitously discovered renal cell carcinoma.

Authors:  M Jayson; H Sanders
Journal:  Urology       Date:  1998-02       Impact factor: 2.649

7.  Transitional cell carcinoma of the renal pelvis and ureter.

Authors:  G R Mufti; J R Gove; D F Badenoch; C G Fowler; R C Tiptaft; H R England; A M Paris; M Singh; M H Hall; J P Blandy
Journal:  Br J Urol       Date:  1989-02

8.  Racial disparity in incidence patterns and outcome of kidney cancer.

Authors:  U N Vaishampayan; H Do; M Hussain; K Schwartz
Journal:  Urology       Date:  2003-12       Impact factor: 2.649

9.  Increased incidental detection and reduced mortality in renal cancer--recent retrospective analysis at eight institutions.

Authors:  Y Homma; K Kawabe; T Kitamura; Y Nishimura; M Shinohara; Y Kondo; I Saito; S Minowada; Y Asakage
Journal:  Int J Urol       Date:  1995-05       Impact factor: 3.369

10.  Prognostic significance of incidental renal cell carcinoma.

Authors:  D Bretheau; E Lechevallier; C Eghazarian; V Grisoni; C Coulange
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

View more
  66 in total

1.  Renal cancer paradox: higher incidence but not higher mortality among African-Americans.

Authors:  Loren Lipworth; Joseph K McLaughlin; Robert E Tarone; William J Blot
Journal:  Eur J Cancer Prev       Date:  2011-07       Impact factor: 2.497

2.  Understanding the limits of large datasets.

Authors:  Catherine M Sanders; Sidney L Saltzstein; Matthew M Schultzel; Duy H Nguyen; Helen Shi Stafford; Georgia Robins Sadler
Journal:  J Cancer Educ       Date:  2012-12       Impact factor: 2.037

3.  Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.

Authors:  Yushi Zhang; Yongqiang Li; Yi Cai; Ke Wang; Hanzhong Li
Journal:  Cell Oncol (Dordr)       Date:  2015-11-23       Impact factor: 6.730

4.  Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size.

Authors:  Brian R Winters; John L Gore; Sarah K Holt; Jonathan D Harper; Daniel W Lin; Jonathan L Wright
Journal:  Urol Oncol       Date:  2015-08-28       Impact factor: 3.498

5.  Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics.

Authors:  Wong-Ho Chow; Brian Shuch; W Marston Linehan; Susan S Devesa
Journal:  Cancer       Date:  2012-11-12       Impact factor: 6.860

6.  Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.

Authors:  Christopher S Hollenbeak; Lucas E Nikkel; Eric W Schaefer; Evo Alemao; Nasrollah Ghahramani; Jay D Raman
Journal:  J Manag Care Pharm       Date:  2011-10

7.  Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Authors:  Che-kai Tsao; Alexander C Small; Max Kates; Erin L Moshier; Juan P Wisnivesky; Benjamin A Gartrell; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  World J Urol       Date:  2012-12-08       Impact factor: 4.226

8.  Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study.

Authors:  Julia Mendoza-Pérez; Jian Gu; Luis A Herrera; Nizar M Tannir; Surena F Matin; Jose A Karam; Maosheng Huang; David W Chang; Christopher G Wood; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2015-12-11       Impact factor: 12.531

9.  Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.

Authors:  Youn-Sang Jung; Su-Jin Lee; Min-Ho Yoon; Nam Chul Ha; Bum-Joon Park
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

10.  Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.

Authors:  Hailiang Zhang; Baijun Dong; Jiade J Lu; Xudong Yao; Shilin Zhang; Bo Dai; Yijun Shen; Yao Zhu; Dingwei Ye; Yiran Huang
Journal:  BMC Cancer       Date:  2009-07-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.